Cargando…
A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis
BACKGROUND: Glycopyrronium tosylate is a topical anticholinergic approved in the USA for primary axillary hyperhidrosis in patients aged ≥ 9 years (Qbrexza™ [glycopyrronium] cloth, 2.4%). OBJECTIVE: This 44-week open-label extension study assessed glycopyrronium tosylate safety and descriptive effic...
Autores principales: | Glaser, Dee Anna, Hebert, Adelaide A., Nast, Alexander, Werschler, William P., Green, Lawrence, Mamelok, Richard D., Quiring, John, Drew, Janice, Pariser, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687675/ https://www.ncbi.nlm.nih.gov/pubmed/31111409 http://dx.doi.org/10.1007/s40257-019-00446-6 |
Ejemplares similares
-
Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis
por: Pariser, David M., et al.
Publicado: (2021) -
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials
por: Pariser, David M., et al.
Publicado: (2018) -
Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study
por: Hebert, Adelaide A., et al.
Publicado: (2020) -
Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials
por: Hebert, Adelaide A., et al.
Publicado: (2018) -
Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use
por: Lamb, Yvette N.
Publicado: (2019)